Loading clinical trials...
Loading clinical trials...
A Phase 1 Randomized, A Phase 1 Randomized, Placebo Controlled, Double Blind, Two Part, Single- and Multiple-Ascending-Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenously Administered ABL301 in Healthy Adult Participants
Conditions
Interventions
ABL301
Placebo
Locations
1
United States
PPD Development, LP
Austin, Texas, United States
Start Date
December 31, 2022
Primary Completion Date
April 30, 2025
Completion Date
April 30, 2025
Last Updated
July 23, 2025
NCT00090662
NCT06716502
NCT06290258
NCT07310264
NCT07483606
NCT06342713
Lead Sponsor
ABL Bio, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions